Marshall Wace
NBSE

Marshall Wace’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Marshall Wace’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,516
Closed -$182K – 4392
2021
Q3 		$182K Sell
2,516
-4,305
-63% -$329K ﹤0.01% 2821
2021
Q2 		$653K Buy
+6,821
New +$753K ﹤0.01% 2005
2020
Q3 		– Sell
-682
Closed -$120K – 2006
2020
Q2 		$120K Buy
+682
New +$114K ﹤0.01% 1446

Other funds holding NBSE

GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CMU
Carnegie Mellon University Pittsburgh, Pennsylvania $64.3M AUM 35.71% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
JAMONY
Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace's NBSE Position: Q4 2021 in Review

Marshall Wace sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q4 2021, closing a stake of 2,516 shares — an estimated $182K sold.

Marshall Wace first reported a position in NBSE in Q2 2020 and held it in 3 quarters. The position peaked at $653K in Q2 2021. 45 funds tracked by Wall St. Rank hold NBSE as of Q4 2021.

  • Marshall Wace reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Marshall Wace sold 2,516 NeuBase Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $182K.
  • Marshall Wace first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2020 and held it in 3 quarters.
  • Marshall Wace's NeuBase Therapeutics, Inc. Common Stock position peaked at $653K in Q2 2021.
  • 45 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Marshall Wace's 13F filing for Q4 2021, filed 14 Feb 2022.